According to a 2009 published report by the American Cancer Society, more than 192,000 people will be diagnosed with breast cancer in 2010. Many of these patients will be treated with some form of chemotherapy. At Rational Therapeutics, we know that selecting the right therapy can mean the difference between life and death.
"In January 2003, Kathy Leach felt a lump in her right breast. After seeking medical advice, a biopsy was performed and her worst fears were confirmed. Kathy, a 45-year-old mother of three, had aggressive breast cancer. After surgery, the prognosis worsened—she had metastatic disease with documented involvement of the liver. Having known of the work of Robert Nagourney, MD, director of Rational Therapeutics, Kathy asked her physicians in Cincinnati to send a sample of her cancer to the California-based laboratory."
The team at Rational Therapeutics has many years of experience conducting laboratory assays on the invasive forms of breast cancers. The laboratory test, known as a "functional profile," enables us to identify those drugs and combinations most likely to kill your cancer.
"From my first meeting with Dr. Nagourney, in 1997, I felt I was in the best of hands and needed to look no further. He took charge of my treatments, referred me to outstanding surgeons, and guided me through my chemotherapy. Thanks to him I was never really sick . . . in spite of my cancer spreading to 13 lymph nodes.".
Most medical oncologists base their treatment strategy on standard chemotherapy protocols for specific types of cancer. For breast cancer patients there are many established drug combinations. These include CMF (cyclophosphamide, methotrexate, fluorouracil), CAF (cyclophosphamide, Adriamycin, fluorouracil), CA (cyclophosphamide plus Adriamycin), Taxol (paclitaxel), Taxotere (docetaxel), Xeloda (capecitabine), Navelbine (vinorelbine), Gemzar (gemcitabine), and Paraplatin (carboplatin). For HER2 positive (Abbreviation for human epidermal growth factor receptor 2) patients, Herceptin (traztuzumab) and Tykerb (lapatinib) are used as well.
These treatments have been developed over years of clinical trials, by assigning patients to different drugs and following their progress to determine the best combination. While some progress has been made, there is no single best treatment for every breast cancer. The fact that at diagnosis all patients with breast cancer have an equal likelihood of response to any given therapy does not mean they will respond equally well. As can be seen from the list above, physicians have many treatment options to choose from. This is why we use functional profiling to select the treatment that is most active for you.
Just like in the cases of, and the other breast cancer patients helped by our staff at Rational Therapeutics, let us find the right treatment for you.